Investor Presentaiton

Diversified Revenue contribution across Geographies (1/2)... METROPOLIS The Pathology Specialist Continue to focus on strengthening the Brand in Focus cities through increase in B2C share while improving the share of Seeding and Other cities through a healthy mix of B2B and B2C driven by our large Test menu Q3FY22 Q3FY23 Revenue Excl. Covid PCR & Covid Allied tests 20% 22% Q3FY22 Q3FY23 Revenue Excl. Covid PCR & Covid Allied tests 232 +20% 278 169 61% 19% 61% 17% 141 20% 48 10% 44 47 28% 60 Q3FY22 Q3FY23 Others Seeding Focus Revenues from our focus cities stood at 61% and the revenue growth was 20% for Q3FY23 on a Y-o-Y basis (Excl. Covid PCR & Allied tests) ✓ Our strategy of increasing revenues from our non-core geographies is panning out. Revenue (Excl. Covid PCR & Allied tests) grew by 28% for our ! other cities for Q3FY23 on a Y-o-Y basis Q3FY22 includes Hitech Diagnostics w.e.f 22nd Oct 2021 14

View entire presentation